CALGB C80802 - PHASE III RANDOMIZED STUDY OF SORAFENIB PLUS DOXORUBICIN VERSUS SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

Objective

This is a clinical trial of sorafenib that will be administered by mouth, which is investigational and doxorubicin that will be administered by IV and is standard of care.

IRB Protocol Number

12-0123

Principal Investigator(s)

WELLS MESSERSMITH

Cancer Trials

• Digestive System Cancer

Sponsor(s)

CALGB

Contact

KIRSTEN MILLER at 720-848-5278
or KIRSTEN.MILLER@UCDENVER.EDU

Eligibility and Other Participant Information

What To Expect : A screening period to determine eligibility. A treatment period(s) that can last up to 3 years. A follow up period will consist of clinic visit // Eligibility criteria include but are not limited to 18 years or older with advanced primary liver cancer.